HSBC/CALL/EVOTEC/42/0.1/18.12.24 Share Price

Warrant

DE000HG3Y703

Real-time BOERSE MUENCHEN 14:37:21 26/06/2024 BST
0.022 EUR 0.00% Intraday chart for HSBC/CALL/EVOTEC/42/0.1/18.12.24
1 month-12.00%
3 months+4.76%
Date Price Change
26/06/24 0.022 0.00%
25/06/24 0.022 0.00%
24/06/24 0.022 0.00%
21/06/24 0.022 0.00%
20/06/24 0.022 0.00%

Real-time BOERSE MUENCHEN

Last update June 26, 2024 at 02:37 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying EVOTEC SE
Issuer HSBC
WKN HG3Y70
ISINDE000HG3Y703
Date issued 20/06/2022
Strike 42
Maturity 18/12/2024 (175 Days)
Parity 10 : 1
Emission price 0.27
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.48
Lowest since issue 0.02
Delta0.08x
Omega 3.485
Premium377.22x
Gearing42.12x
Moneyness 0.2106
Difference Strike 33.16
Difference Strike %+78.96%
Spread 0.016
Spread %55.17%
Theoretical value 0.0210
Implied Volatility 123.77 %
Total Loss Probability 98.75 %
Intrinsic value 0.000000
Present value 0.0210
Break even 42.21 €
Theta-0x
Vega0x
Rho0x

Company Profile

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Sector
-
More about the company

Ratings for Evotec SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Evotec SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.825 EUR
Average target price
20.79 EUR
Spread / Average Target
+135.58%
Consensus